Pfizer (NYSE:PFE) has been given a $46.00 price objective by analysts at JPMorgan Chase & Co. in a note issued to investors on Monday, July 29th, Borsen Zeitung reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 29.69% from the stock’s current price.
Other equities analysts also recently issued research reports about the stock. Morgan Stanley assumed coverage on shares of Pfizer in a research note on Tuesday, June 4th. They issued an “overweight” rating and a $48.00 target price for the company. Zacks Investment Research upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a research note on Wednesday, April 10th. Bank of America lifted their target price on shares of Pfizer from $45.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. Barclays reiterated a “hold” rating and issued a $41.00 target price on shares of Pfizer in a research note on Thursday, May 9th. Finally, Goldman Sachs Group reiterated a “buy” rating and issued a $49.00 target price on shares of Pfizer in a research note on Monday, June 17th. Fourteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $46.56.
Shares of PFE stock opened at $35.47 on Monday. The company has a market capitalization of $204.99 billion, a price-to-earnings ratio of 11.82, a price-to-earnings-growth ratio of 2.94 and a beta of 0.63. The company has a current ratio of 1.54, a quick ratio of 1.27 and a debt-to-equity ratio of 0.60. Pfizer has a 52 week low of $35.86 and a 52 week high of $46.47. The stock has a 50-day moving average of $41.55.
In related news, insider Alexander R. Mackenzie sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the completion of the transaction, the insider now owns 80,094 shares of the company’s stock, valued at $3,524,136. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Frank A. Damelio sold 153,184 shares of the business’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the completion of the transaction, the executive vice president now directly owns 489,647 shares of the company’s stock, valued at approximately $21,588,536.23. The disclosure for this sale can be found here. 0.09% of the stock is currently owned by insiders.
Hedge funds have recently added to or reduced their stakes in the business. Evolution Wealth Advisors LLC purchased a new position in Pfizer in the 2nd quarter worth approximately $34,000. IMA Wealth Inc. lifted its holdings in shares of Pfizer by 144.5% in the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 477 shares during the last quarter. Winch Advisory Services LLC lifted its holdings in shares of Pfizer by 69.6% in the 4th quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 336 shares during the last quarter. Ruggie Capital Group bought a new stake in shares of Pfizer in the 4th quarter worth approximately $44,000. Finally, Financial Gravity Wealth Inc. lifted its holdings in shares of Pfizer by 33.2% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 257 shares during the last quarter. 71.81% of the stock is owned by institutional investors and hedge funds.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: What is a balanced fund?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.